Structure Therapeutics Announces Upsized $547.4 Million Public Offering
San Diego – June 7, 2024 – Cooley advised Structure Therapeutics (Nasdaq: GPCR), a global, clinical-stage biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, on its upsized $547.4 million underwritten public offering. Structure Therapeutics offered and sold 10,427,017 American depositary shares (ADSs) priced at $52.50 per ADS, which included an option for the underwriters to purchase an additional 1,360,045 ADSs.
Partners Patrick Loofbourrow, Charlie Kim and Jean Park led the Cooley team advising Structure Therapeutics.
Cooley previously advised Structure Therapeutics on its $300 million private placement in October 2023 and $185.3 million initial public offering in February 2023.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has more than 1,300 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.